Connect with us

Hi, what are you looking for?

Alive Business PlanAlive Business Plan

Stock

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

By Patrick Wingrove

(Reuters) – Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE:NVO), hopes to double the size of its recently acquired contract drugmaker Catalent (NYSE:CTLT) over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Novo Holdings last month closed a $16.5 billion deal to buy U.S.-based Catalent. The firm then sold three of Catalent’s plants used to complete the drug manufacturing process to Novo Nordisk for $11 billion as part of the deal, to help the Danish drugmaker ramp up supplies of its popular weight-loss drug Wegovy.

Jonathan Levy, the Novo Holdings partner who led the deal, in an interview this week said his firm did not want to overcommit to a revenue target before it had a chance to set out a corporate strategy with Catalent’s management.

“But doubling the size of your business over five years is always a nice barometer to work on, and I think we could do something more here from an enterprise value perspective,” Levy told Reuters at the JPMorgan health conference in San Francisco.

Catalent, which had sales of $4.38 billion in 2024, will hold its next board meeting in February, according to Levy.

Levy said he expects more drugmakers that currently rely on manufacturers in China and India to look for western service providers with Trump set to return to the White House on Monday, given his America first focus.

Catalent and Thermo Fisher Scientific (NYSE:TMO) unit Patheon — two of the largest contract drug manufacturers based in the U.S. — could be beneficiaries of such moves.

In addition to his outspoken preference for U.S. manufacturing, Trump has said he will hit China with new tariffs on the first day of his presidency, but Levy did not discuss how that might affect pharmaceuticals.

Levy said Novo Holdings has a venture vehicle with more than 90 biopharmaceutical assets that will be “a tremendous pipeline” for Catalent.

He also said he was closely watching lawmaker efforts to pass a bill that would restrict U.S. business with certain Chinese biotechnology companies, including contract drug manufacturer WuXi AppTec.

“Companies like WuXi, for example, they (will) struggle as a result of it,” Levy said, “and companies like Catalent will benefit.”

This post appeared first on investing.com
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    You May Also Like

    Latest News

    The Gateway Pundit, a far-right website, published a note from its editor on Saturday acknowledging that two election workers in Georgia did not engage...

    Latest News

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Investing

    JAKARTA (Reuters) -Indonesia has asked Alphabet (NASDAQ:GOOGL)’s Google and Apple (NASDAQ:AAPL) to block Chinese fast fashion e-commerce firm Temu in their application stores in...

    Latest News

    New majorities in Congress, particularly when the incoming party has a new leader, offer the rare chance for the institution to take a breath...



    Disclaimer: alivebusinessplan.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 alivebusinessplan.com